REPL - Replimune Group, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.85
-0.35 (-2.46%)
As of 1:16PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close14.20
Open14.26
Bid13.70 x 800
Ask14.26 x 800
Day's Range13.85 - 14.58
52 Week Range10.52 - 63,999.00
Volume1,977
Avg. Volume70,284
Market Cap437.019M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Replimune to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology

    WOBURN, Mass., Sept. 26, 2018 -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today.

  • GlobeNewswire2 months ago

    Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1

    Replimune Group Inc. (REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application for its lead product candidate, RP1, for patients with solid tumors. The Company intends to open its ongoing Phase 1/2 clinical trial in the U.S. and begin enrolling patients in the fourth quarter of 2018. The clinical trial is currently ongoing in the U.K., as previously announced.

  • GlobeNewswire2 months ago

    Replimune Reports Financial Results for the First Fiscal Quarter, Ended June 30, and Provides Development and Corporate Update

    “With the completion of our successful initial public offering, Replimune is well funded to advance our new generation of oncolytic immunotherapy product candidates derived from our Immulytic platform through clinical trials in multiple tumor types and to establish in-house manufacturing capabilities,” said Robert Coffin, Ph.D., co-founder and CEO of Replimune. “We are pleased with the preparations underway to initiate clinical studies under our collaboration agreements with Bristol-Myers Squibb, entered in February, for the development of RPI in combination with the anti-PD-1 antibody nivolumab, and with Regeneron, entered in May, for the development of RP1 in combination with the anti-PD1 antibody cemiplimab.

  • Benzinga3 months ago

    BMO Sees A Low-Risk Biotech Buy In Replimune

    Biotech Replimune Group, Inc. (NASDAQ: REPL ), which conducts research and cancer treatment studies using oncolytic viruses, picked up a sell-side bull Tuesday. The Analyst BMO Capital Markets analyst ...